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Abstract
Human immunodeﬁciency virus (HIV), hepatitis B virus (HBV) and
hepatitis C virus (HCV) aremajor public health concerns.We aimed
to determine the prevalence of HBV and HCV infections among
HIV-infected patients, and to identify the main circulating hepatitis
strains in Morocco. The study was carried out in 503 HIV-infected
patients. Our survey indicated that the prevalence of HIV/hepatitis
co-infection was 10.6%; 5.2% of patients were HBV surface antigen
positive, and 5.4% of patients were anti-HCV positive. Among the
HBV surface antigen-positive group, HBV DNA sequencing identi-
ﬁed exclusively genotype D (D1: 26.7%; D7: 73.3%) in accordance
with what is found in the general population. In contrast, sequencing
of HCV isolates produced an unusual subtype distribution with a
decreasing order of prevalence: 1a, 3a (both 23.5%), 1b, 4a (both
17.6%), 1c (11.8%) and 6h (6%).
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Introduction
Infections with human immunodeﬁciency virus (HIV), hepa-
titis B virus (HBV) and hepatitis C virus (HCV) rank among
the ten leading causes of death from infectious diseases
[1].
Current data show that the variability in the prevalence of
HIV/hepatitis co-infection worldwide is multifactorial, and
depends on the geographic regions, the infection risk factors,
and the type of exposure [2,3]. In Morocco, the WHO
estimated that in 2008, about 21 000 people were living with
HIV infection [4].
To the best of our knowledge, HIV/hepatitis co-infection is
still poorly documented and more information is needed to
better understand the Moroccan context. The aim of the
present study was, therefore, to characterize epidemiological
and molecular aspects of HIV/hepatitis co-infection in a
Moroccan cohort of HIV-infected patients.
This study included a cohort of 503 HIV-infected patients
(245 men and 258 women) followed for treatment in the
Infectious Disease Centre, CHU Ibn Rochd, Casablanca from
January 2006 to June 2010. Sociodemographic parameters and
clinical data (disease diagnosis, antiretroviral treatment, labo-
ratory values, alcohol consumption and drug use history) were
extracted in detail from the department clinical database
Nadis [5]. The study was approved by the ethics committee
of Institut Pasteur of Morocco, and privacy and conﬁdentiality
conditions were guaranteed.
For all patients with HIV infection, serological markers for
HBV (HBV surface antigen (HBsAg), HBV e-antigen (HBeAg),
and antibodies to HB surface antigen, core antigen and e-antigen
(anti-HBs, anti-HBc, anti-HBe)) and HCV (anti-HCV antibodies)
were tested with commercially available kits (AxSYM; Abbott
Laboratories, Wiesbaden-Delkenheim, Germany), and for hep-
atitis D virus (IgG-Ab) using ETI-AB-DELTAK-2 (DiaSorin S.P.A,
Saluggia, Italy). Positive samples for HBsAg and anti-HCV
antibodies were made available for further molecular analysis
(PCR, reverse transcription-PCR and genotyping).
HBV DNA and HCV RNA were isolated using the QIAamp
Viral extraction Kit (QIAgen,Valencia, CA, USA), according to
the manufacturer’s instructions.
Plasma HCV RNA and HBV DNA were quantiﬁed by real-
time PCR using Syber Green PCR Master Mix (Applied
Biosystems, Foster City, CA, USA) on a thermocycling
machine according to the manufacturer’s instructions (ABI
PRISM 7000; Applied Biosystems).
For genotyping, the HBV surface (S) gene was ampliﬁed as
previously described [6]. HCV RNA was isolated and cDNA
was synthesized using the Moloney murine leukaemia virus
reverse transcriptase (M-MLV RT) (Invitrogen, Saint Aubin,
France), according to the manufacturers’ instructions, and then
ampliﬁcation was carried out using primers matching con-
served regions in the 5′-untranslated region and NS5B using
conditions previously described [7,8].
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Positive PCR products were puriﬁed using the Exonuclease
I/Shrimp Alkaline Phosphatase (GE Healthcare, Chalfont
St Giles, UK) and bidirectionally sequenced using BigDye
Terminator version 3.1 kits and an ABI PRISM 3130 DNA
automated sequencer (Applied Biosystems). Sequence analysis
was performed with SEQSCAPE v2.5 software (Applied Biosys-
tems) by comparing the study sequences to a set of reference
sequences using BLAST.
Results were reported as mean and standard deviation or
median and range for continuous variables, and frequency
counts for categorical variables. Categorical variables were
evaluated using chi-squared or Fisher’s exact test. One-way
analysis of variance was conducted to compare mean quantita-
tive values. All p-values were two sided, and differences with
p <0.05 were considered to be statistically signiﬁcant. All
statistical analyses were performed using the Statistical Package
for Social Sciences (SPSS) program (SPSS Inc., Chicago, IL, USA).
Baseline characteristics of the patients are described in
Table 1. Patients were grouped into HIV/HBV co-infected,
HIV/HCV co-infected, and HIV mono-infected (HIV+) patients,
according to serological and molecular data as described
below (Table 2).
From 503 HIV-positive patients, 148 (29.4%) were found to
be anti-HBc positive, 93 (18.5%) had anti-HBs (nine patients
with only anti-HBs and 84 patients with both anti-HBs and anti-
HBc), whereas 26 (5.2%) were positive for HBsAg (Table 2).
Anti-delta IgG-Ab was sought in all HBV-infected patients, but
none was found. HBV DNA was undetectable for 11 patients
(42.3%), but the remaining HBsAg(+) patients had detectable
DNA (15/26, 57.7%). Sequencing and phylogenetic analysis of
the surface gene indicated that HBV strains belonged exclu-
sively to genotype D (D7: 73.3%, D1: 26.7%).
Twenty-seven cases (5.4%) within the cohort studied had
anti-HCV antibodies, and viral RNA load was subsequently
measured in these patients. HCV RNA was undetectable for
eight patients (29.6%). Among the 19 (70.4%) HIV/HCV co-
infected patients positive for HCV RNA, 17 were successfully
sequenced, and genotype 1 (9/17, 52.9%) was present in the
majority of cases, but distributed among three subtypes (1a,
23.5%; 1b, 17.6%; 1c, 11.8%). Sizeable subsets of HCV strains
were composed of 3a and 4a subtypes (23.5% and 17.6%,
respectively).
According to the CDC staging system of HIV disease,
patients were classiﬁed as CDC (A/B) and CDC (C) stages.
Interestingly, we found a signiﬁcant association between HIV/
hepatitis co-infection, and advanced HIV disease stage; 39.7%
of HIV/hepatitis patients versus 26.7% of HIV+ only patients
(p 0.0187) had CDC (C) stage disease. Among the HBV-DNA-
positive patients and HCV-RNA-positive group, 61% and 41%
had CDC (C) stage disease, respectively.
TABLE 1. Characteristics of human immunodeﬁciency virus
(HIV) -infected patient’s cohort at the time of enrolment
HIV
mono-
infected
HIV/Hepatitis
co-infected p
Total 450 53
Age (mean  SD), year 38  9 40  7 0.048
Sex
Male 203 42 2.0E-6
Female 247 11
Ethnic groups
Moroccan 442 52 0.393
Foreigners living in Morocco 8 1
Transmission route
Sexual contact 420 38 1.0E-5
Injecting drug use 5 7 4.0E-5
Pregnancy 3 0 0.715
Blood transfusion 2 0 0.800
Others 20 8 0.004
Antiretroviral therapy
Yes 350 45
No 100 8 0.073
CD4 cell count (cells/mm3)
<350 291 36
>350 159 17 0.097
CDC Stage
A/B 330 32 0.018
C 120 21
HIV load
<1000 copies/mL 112 21 0.019
>1000 copies/mL 307 32
TABLE 2. Molecular, clinicopathological parameters and
seroprevalence of human immunodeﬁciency virus (HIV)/
hepatitis B virus (HBV) and HIV/hepatitis C virus (HCV)
co-infected patients
Co-infected
B (HBsAg+)
Co-infected
C (HCV Ab+)
n = 26 n = 27
Serological markers
Anti-HBs 0 8 (29.6%)
Anti-HBc 26 (100%) 14 (51.8%)
HBeAg 7 (26.9%) 0
Anti-HBe 17 (65.4%) –
Age (mean  SD), year 40  7
Sex
Male 18 (69.2%) 24 (88.9%)
Female 8 (30.8%) 3 (11.1%)
Antiretroviral therapy
Yes 25 (96%) 20 (74%)
No 1 (4%) 7 (26%)
CD4 cell count (cells/mm3)
<350 19 (73%) 17 (63%)
>350 7 (27%) 10 (37%)
CDC stage
A/B 14 (53.8%) 18 (66.7%)
C 12 (46.2%) 9 (33.3%)
HIV load before co-infection (copies/mL)
Low <1000 copies/mL 8 (30.8%) 13 (48.2%)
High >1000 copies/mL 18 (69.2%) 14 (51.8%)
AST (median  SD), IU/L 48  29 64  62
ALT (median  SD), IU/L 52  43 76  99
HBV DNA+ 15 (57.7%) –
HCV RNA+ – 19 (70.4%)
Median hepatitis viral load
(copies/mL)
722.35 (0; 16 242 857) 11969 (0; 5 437 827)
Genotypes and subgenotypes D7 (73.3%)
D1 (26.7%)
1a (23.5%)
1b (17.6%)
1c (11.8%)
3a (23.5%)
4a (17.6%)
6 h (6%)
anti-HBc, anti-HBV core antigen; anti-HBe, anti-HBV e-antigen; anti-HBs, anti-HBV
surface antigen; ALT, alanine aminotransferase; AST, aspartate aminotransferase;
HBeAg, HBV e-antigen.
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Morocco is a country of intermediate endemicity for hepatitis
B and C. A recent survey of HBsAg carriage reported a
prevalence of 1.66% whereas another one showed an anti-HCV
prevalence of 1.93% [9–11]. In the current study, we have shown
that prevalence of HIV/hepatitis co-infection was 5.2% for HIV/
HBV and 5.4% for HIV/HCV within the Moroccan HIV-infected
population. This indicated that HIV-infected patients form a
high-risk group for HBV and HCV co-infection compared with
the general population. This is probably because the three
viruses share similar routes of transmission [2].
Co-infection with HIV/hepatitis in the North African
context is still poorly studied. The prevalence of co-infection
with HCV has been reported to be variable, and dependent on
the route of transmission [2].
In Tunisia, a prevalence of 40% anti-HCV positivity has been
reported among HIV-infected patients, of whom 78% were
injecting drug users [12,13]. In Algeria, the prevalence of anti-
HCV among HIV-infected patients has been measured to be
6% [14]. In Morocco, Benjelloun et al. [15] reported that the
prevalence of HIV/HCV co-infections two decades ago was
approximately 20%. The discordance of these results and the
present report can be explained by the fact that the HIV-
positive group studied in 1996 were mostly injecting drug
users or professional sex workers. Such populations were
obviously at high risk for additional viral infections among
which hepatitis C is prominent [16]. In the present study, the
group surveyed was a component of the general population,
and not just a subset of high-risk individuals. Hence, these
patients had different socio-economic backgrounds, and
accordingly the main route of HIV infection was heterosexual
contact. In fact, of the 503 patients included in this study, only
12 patients had a history of injection drug use, of whom seven
patients were found to be anti-HCV positive. Finally, recent
informational campaigns (since 2004) have increased Moroccan
public awareness about preventive measures against infection
with HIV. Hence, it is hypothesized that such policies have
already had an impact in reducing the incidence of HIV/HCV
co-infections in the Moroccan population.
As in all Mediterranean countries, the genotype D is the
predominant HBV genotype in the Moroccan population [6].
The same also holds true in HIV-infected patients. Most
genotype D strains are classiﬁed as D7 subtype (73.3%),
whereas the remaining 26.7% are subtype D1. This result is
consistent with earlier studies from the Maghreb [6,17]. With
regards to HIV/HCV co-infection, our results showed that
subtype 1b isolates are closely related to the previously
published Maghrebian and European strains. In HIV(+) patients,
subtype 1b is no longer the predominant genotype as has been
reported in HIV() Moroccan patients with chronic hepatitis
C (67.5%) or HCV-associated hepatocellular carcinoma
(84.4%) [7]. Additional phyla of genotype 1 (subtypes 1a and
1c) are also present in co-infected patients whereas they are
almost absent from HIV() populations. In contrast to what
has been observed in the general population where the
ancestral West African genotype 2 closely follows subtype 1b,
we observed striking prevalences of subtypes 3a and 4a (23.5%
and 17.6%, respectively) in co-infected patients [7]. Such HCV
subtype distributions in the HIV/HCV co-infected population
was somewhat unexpected. This result shows that the
epidemiology of hepatitis virus strains circulating among HIV
(+) patients is much more complex than what we observed in
HIV() patients. Such diversity could be reasonably explained
by the geographical, familial and economic connections devel-
oped between Morocco and Europe (3a), the Middle East (4a),
and in particular countries like France, Italy, Egypt and Saudi
Arabia. A similar situation was not found in the case of the less
diverse HBV isolates for which genotype D has been found to
be predominant from Morocco to India.
In conclusion, the endemicities of chronic hepatitis viral
infections in Morocco put HIV-infected patients at high risk for
co-infection with these agents. The current study provides an
epidemiological overview of the HIV/hepatitis co-infection
situation in the country, and emphasizes the urgent need for
the rapid implementation of more efﬁcient preventive and
monitoring programmes.
Acknowledgements
The authors would like to acknowledge all patients for their
participation in this study and the Association de lutte contre
le SIDA (ALCS). We are particularly grateful to Prof. Christian
Trepo for useful review of the manuscript, to Dr Pascal Pineau
for advice, rich commentary and critical reading of the
manuscript, and to Prof. George Y. Wu for pertinent English
revision of the manuscript. This work was supported by The
Fonds d’Appui Structure Partenaire (FASP).
Transparency Declaration
The authors who have taken part in this study declared that
they do not have anything to disclose regarding funding or
conﬂict of interest with respect to this manuscript.
References
1. Alter MJ. Healthcare should not be a vehicle for transmission of
hepatitis C virus. J Hepatol 2008; 48: 2–4.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, E454–E457
E456 Clinical Microbiology and Infection, Volume 19 Number 10, October 2013 CMI
2. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol
2006; 44: 6–9.
3. Lazarus JV, Shete PB, Eramova I, Merkinaite S, Matic S. HIV/hepatitis
coinfection in eastern Europe and new pan-European approaches to
hepatitis prevention andmanagement. Int J Drug Policy 2007; 18: 426–432.
4. World Health Organization. Hepatitis B Hepatitis C and HIV/AIDS
Factsheets. 2011. Available at: http://www.who.int/mediacentre/
factsheets/en (last accessed 12 April 2012).
5. Pugliese P, Cuzin L, Enel P. NADIS 2000, development of an electronic
medical record for patients infected by HIV HBV and HCV. Presse Med
2003; 32: 299–303.
6. Kitab B, Essaid El Feydi A, Aﬁﬁ R et al. Hepatitis B genotypes/
subgenotypes and MHR variants among Moroccan chronic carriers.
J Infect 2011; 63: 66–75.
7. Brahim I, Akil A, Mtairag EM et al. Morocco underwent a drift of
circulating hepatitis C virus subtypes in recent decades. Arch Virol 2011;
14: 102–104.
8. Utama A, Tania N, Dhenni R et al. Genotype diversity of hepatitis C
virus (HCV) in HCV-associated liver disease patients in Indonesia. Liver
Int 2010; 30: 1152–1160.
9. Sbai A, Baha W, Ougabrai H et al. Prevalence de l’infection par le virus
de l’hepatite B et l’evaluation des facteurs de risque au Maroc. Pathol
Biol 2011; 60: 65–69.
10. Benouda A, Boujdiya Z, Ahid S, Abouqal R, Adnaoui M. Prevalence de
l’infection par le virus de l’hepatite-C au Maroc et evaluation des tests
serologiques de depistage pour la prediction de la viremie. Pathol Biol
2009; 57: 368–372.
11. Ezzikouri S, Pineau P, Benjelloun. S. Hepatitis B virus in the Maghreb
region: from epidemiology to prospective research. Liver Int 2013; doi:
10.1111/liv.12135.
12. Kilani B, Ammari L, Marrakchi C et al. Seroepidemiology of HCV-HIV
coinfection in Tunisia. Tunis Med 2007; 85: 121–3.
13. Maaref F, Kilani B, Ammari L et al. Prevalence de l’hepatite G et des
hepatites virales B et C dans la population VIH(+) de l’ho^pital La Rabta,
Tunis, Tunisie. Pathol Biol 2011; 59: 213–216.
14. Berkane S. French Luncheon comment prendre en charge les patients
atteints d’hepatite C avec les medicaments disponibles en Algerie 2009.
15. Benjelloun S, Bahbouhi B, Sekkat S, Bennani A, Hda N, Benslimane A.
Anti-HCV seroprevalence and risk factors of hepatitis C virus infection
in Moroccan population groups. Res Virol 1996; 147: 247–255.
16. Hagan H, Thiede H, Des Jarlais D. HIV/hepatitis C virus co-infection in
drug users: risk behavior and prevention. AIDS 2005; 19(Suppl 3):
S199–S207.
17. Meldal B, Moula N, Barnes I, Boukef K, Allain J. A novel hepatitis B virus
subgenotype, D7, in Tunisian blood donors. J Gen Virol 2009; 90: 1622–
1628.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, E454–E457
CMI Khadija et al. HBV and HCV in patients with co-existing HIV E457
